Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05359679 · ClinicalTrials.gov registry record · NA

Can Value Champions Reduce Inappropriate Prescribing for People With Dementia?

A NA study, sponsored by Kaiser Permanente.

Completed
Registry status
NA
Development phase
3,300
Enrollment target

NCT05359679: Completed NA study, sponsored by Kaiser Permanente.

NCT05359679 is a NA study that has completed, run by Kaiser Permanente. The registered enrollment target is 3,300 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (135% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05359679, a NA study, has completed, sponsored by Kaiser Permanente.

COMPLETED
Registry status
NA
Development phase
3,300 participants
Enrollment target

Study Summary

The primary objective is to assess the effectiveness of training a clinician to be a 'value champion' within clinical settings to decrease the use of three classes of potentially inappropriate prescription medications (PIMs) among people living with dementia (PLWD). Secondary objectives include determining if the intervention is associated with a reduction in emergency department (ED) visits or hospitalizations due to a fall, and examining five implementation outcomes: appropriateness, feasibility, fidelity, penetration, and equity. This study is a pragmatic cluster-randomized trial to test the effectiveness of a primary care clinician value champion for de-implementing PIMs among patients 65 years of age and older with a diagnosis of dementia. Medicare Part D pharmacy claims data will be analyzed at the end of the 12-month intervention for the primary outcome, the medication possession rates (MPR) for three groups of potentially inappropriate medications: antipsychotic medications, benzodiazepines, and hypoglycemic medications (sulfonylureas and insulin). In a similar fashion, a hospital admission, or an emergency department visit for a fall will be assessed at the end of the intervention using Medicare claims data. Finally, the five implementation outcomes will be evaluated at the end of the intervention from notes entered by the value champions in project workbooks. Primary care clinics within each of the two participating ACOs will be randomized to either the intervention or control arms of the study. Prior to random assignment, the investigators will stratify practices based on high versus low historic prescribing rates. A primary care clinician from each clinic selected for the trial in the intervention arm (n=30 across the two ACOs) will be recruited as a clinician value champion for each intervention clinic. The clinician value champion will participate in twice monthly value champion web-based training sessions for six months and then launch a 12-month in

Primary Outcome

The Medication Possession Ratio is calculated from Medicare Part D claims data as quotients with denominator equal to the length of the quarter and the numerators equal to the days supply for prescriptions within the medication class filled during the quarter, plus excess days-supply from the previous period minus excess days-supply remaining at the end.

Interventions

  • OTHER No Intervention
  • BEHAVIORAL Value Champion Training Program

Trial Details

FieldValue
Enrollment Target 3,300 participants
Start Date 2023-08-30
Est. Completion 2023-10-31
Phase NA
Kaiser Permanente

294 total trials

What the finished NCT05359679 record still lists

NCT05359679 is an interventional study that assigns participants to a tested intervention. Its 3,300 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (135% higher).

The record links to 0 conditions, and to 2 interventions - of which No Intervention is the first listed.

NCT05359679 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05359679 about?

NCT05359679 is a clinical study titled "Can Value Champions Reduce Inappropriate Prescribing for People With Dementia?". The primary objective is to assess the effectiveness of training a clinician to be a 'value champion' within clinical settings to decrease the use of three classes of potentially inappropriate prescription medications (PIMs) among people living with dementia (PLWD). Secondary objectives include dete...

What is the current status of trial NCT05359679?

This trial is currently completed. It is a NA study. The enrollment target is 3,300 participants. The study started on 2023-08-30. Estimated completion is 2023-10-31.

What interventions are being tested in trial NCT05359679?

The interventions under investigation include: No Intervention (OTHER), Value Champion Training Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT05359679?

This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05359679's enrollment target sits among peer trials

3,300 37th of 2000 higher than 1,964 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07214610 · 3,300 participants · NA

    Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study

  • NCT03674307 · 3,306 participants · NA

    Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates

  • NCT06815536 · 3,291 participants

    Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae

  • NCT06543446 · 3,290 participants · NA

    Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05359679, the US trial registry maintained by the National Library of Medicine. NCT05359679 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.